Eli Lilly, venture fund and Andreessen Horowitz

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...
Boltwood Capital Management lessened its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 2.0% during the fourth quarter, according to its most recent 13F filing with the SEC.
The newly launched biotech is equipped with rights to a trio of weight loss medicines licensed from China-based Sciwind ...
View Eli Lilly and Company (LLY) current and estimated P/E ratio data provided by Seeking Alpha.
Versant Capital Management Inc increased its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 19.2% during the 4th quarter, Holdings Channel.com reports. The fund owned 1,167 shares of the ...
The Business Journal has the list of the Massachusetts biotech companies that raised the largest venture capital rounds in the last year. Meet the most-capitalized companies of 2024.
Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers ...